Azithromycin Monograph

Introduction/Overview

Azithromycin is a semi‑synthetic macrolide antibiotic widely employed in the treatment of various bacterial infections. Its broad spectrum activity, favorable pharmacokinetic profile, and convenient dosing regimens have cemented its position in contemporary antimicrobial therapy. The clinical relevance of azithromycin extends beyond traditional respiratory tract infections to include sexually transmitted infections, skin and soft tissue infections, and prophylaxis against certain opportunistic pathogens in immunocompromised hosts. A comprehensive understanding of its pharmacological attributes is indispensable for clinicians and pharmacists alike, ensuring optimal therapeutic outcomes while mitigating adverse events.

Learning objectives for this chapter include:

• Describe the chemical and pharmacological classification of azithromycin.
• Explain the molecular basis of its antibacterial activity.
• Summarize key pharmacokinetic parameters and their clinical implications.
• Identify approved and commonly used off‑label indications.
• Recognize major adverse effects, contraindications, and drug interactions.
• Apply special considerations when prescribing azithromycin in pregnancy, lactation, pediatrics, geriatrics, and patients with organ dysfunction.

Classification

Drug Classes and Categories

Azithromycin belongs to the macrolide class of antibiotics, characterized by a 14‑membered lactone ring. Within this class, it is classified as a second‑generation macrolide, reflecting structural modifications that confer enhanced activity against certain resistant organisms. The drug is further categorized as a semi‑synthetic derivative of erythromycin, possessing a 4‑azido substitution that augments its pharmacodynamic properties.

Chemical Classification

The molecular formula of azithromycin is C₃₈H₆₈N₂O₁₂, with a molecular weight of 748.97 g mol^-1. It is a complex glycopeptide containing a sugar moiety (desosamine) and a macrocyclic lactone core. The presence of the 4‑azido group enhances its lipophilicity, facilitating extensive tissue penetration and prolonged intracellular retention.

Mechanism of Action

Pharmacodynamics

Azithromycin exerts its antibacterial effect by binding to the 50S subunit of the bacterial ribosome, specifically the 23S rRNA component. This interaction inhibits the translocation step of protein synthesis, effectively halting peptide elongation. The inhibition is concentration‑dependent and displays a post‑antibiotic effect, allowing for less frequent dosing schedules.

Receptor Interactions

Binding occurs at a site overlapping the macrolide, ketolide, and lincosamide binding region. The drug’s affinity for the 50S subunit is higher than that of earlier macrolides, contributing to its activity against macrolide‑resistant strains that possess target site mutations. Competitive binding to the ribosomal exit tunnel prevents the passage of nascent peptides, thereby disrupting bacterial growth.

Molecular/Cellular Mechanisms

At the cellular level, azithromycin accumulates within phagocytic cells, such as neutrophils and macrophages, reaching concentrations that are several times higher than those in plasma. This intracellular sequestration permits sustained antimicrobial activity against intracellular pathogens (e.g., Chlamydia trachomatis, Mycobacterium tuberculosis). Additionally, the drug exhibits anti‑in, attenuating the release of pro‑inflammatory cytokines, which may contribute to clinical benefits in respiratory conditions unrelated to infection.

Pharmacokinetics

Absorption

Oral absorption of azithromycin is moderate, with a bioavailability of approximately 37 %. Absorption is enhanced by food intake, particularly high‑fat meals, which increase gastrointestinal transit time and solubilize the drug. Peak plasma concentrations (C_max) are typically reached within 2–4 h post‑dose in fasting subjects, and within 3–6 h when taken with food.

Distribution

Azithromycin demonstrates extensive distribution into tissues, with a volume of distribution (V_d) ranging from 500 to 700 L. The drug’s lipophilicity and positive charge at physiological pH facilitate penetration into epithelial cells, alveolar macrophages, and other immune cells. Tissue concentrations can exceed plasma levels by factors of 5–50, depending on the site of infection.

Metabolism

The drug undergoes limited hepatic metabolism, primarily via hepatic transporters rather than cytochrome P450 enzymes. Consequently, hepatic impairment affects azithromycin pharmacokinetics to a lesser extent compared with many other antibiotics.

Excretion

Renal elimination accounts for approximately 11 % of the administered dose, with the remaining drug being excreted via biliary routes into feces. The urinary concentration of azithromycin is low compared with other macrolides, which may reduce the risk of nephrotoxicity.

Half‑Life and Dosing Considerations

The terminal half‑life (t_1/2) of azithromycin is unusually prolonged, typically around 68 h in healthy adults. This extended t_1/2 supports once‑daily dosing and shorter treatment courses. For example, a standard regimen for community‑acquired pneumonia involves 500 mg on day 1 followed by 250 mg daily for 4 days. Alternative dosing schedules, such as a 5‑day regimen of 500 mg on days 1–3 followed by 250 mg on days 4–5, are also employed for other indications.

Therapeutic Uses/Clinical Applications

Approved Indications

• Community‑acquired bacterial pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, and atypical pathogens.
• Acute exacerbations of chronic obstructive pulmonary disease (COPD) where bacterial infection is implicated.
• Acute sinusitis and otitis media, particularly in patients intolerant to first‑line agents.
• Sexually transmitted infections such as Chlamydia trachomatis, Neisseria gonorrhoeae (combined with ceftriaxone), and Mycoplasma genitalium.
• Skin and soft tissue infections caused by Staphylococcus aureus (including MRSA) and Streptococcus pyogenes.
• Prophylaxis of Mycobacterium avium complex in patients with cystic fibrosis.

Off‑Label Uses

Azithromycin is frequently employed in the following off‑label scenarios:

1. Management of inflammatory airway diseases such as asthma and bronchiectasis, leveraging its anti‑inflammatory effects.
2. Prevention of recurrent respiratory tract infections in patients with immunodeficiencies.
3. Treatment of Lyme disease and other tick‑borne illnesses in combination with doxycycline.
4. Adjunctive therapy in community‑acquired pneumonia when coverage for atypical organisms is desired.

Adverse Effects

Common Side Effects

• Gastrointestinal disturbances, including nausea, vomiting, abdominal pain, and diarrhea.
• Headache and dizziness, particularly during the initial days of therapy.
• Altered taste sensation (dysgeusia) reported in a minority of patients.

Serious or Rare Adverse Reactions

• Cardiac arrhythmias (e.g., QT interval prolongation, torsades de pointes) especially in patients with pre‑existing conduction defects or electrolyte abnormalities.
• Hepatotoxicity manifested as elevated transaminases, jaundice, or, rarely, acute hepatic failure.
• Allergic reactions ranging from mild urticaria to anaphylaxis.
• Hearing impairment, although uncommon, has been reported in high‑dose or prolonged therapy.

Black Box Warnings

Azithromycin carries a black box warning regarding the potential for ventricular arrhythmias and sudden cardiac death due to QT interval prolongation. The risk is amplified in patients with congenital long QT syndrome, electrolyte disturbances, or concurrent use of other QT‑prolonging agents.

Drug Interactions

Major Drug‑Drug Interactions

• Azithromycin can prolong the QT interval when combined with other agents possessing similar effects, such as certain antiarrhythmics (e.g., sotalol), antipsychotics (e.g., haloperidol), and antifungals (e.g., ketoconazole).
• Concomitant use with rifampicin or rifabutin may reduce azithromycin plasma concentrations by inducing hepatic transporters.
• Azithromycin is a substrate of P‑glycoprotein; inhibitors of this transporter (e.g., clarithromycin) could potentially elevate azithromycin levels.
• Co‑administration with oral contraceptives may modestly increase estrogen levels, although clinical significance remains uncertain.

Contraindications

• Known hypersensitivity to azithromycin or other macrolides.
• Severe hepatic impairment (Child‑Pugh class C) due to altered pharmacokinetics.
• Patients with documented QT prolongation or a history of ventricular arrhythmias.

Special Considerations

Use in Pregnancy and Lactation

Azithromycin is classified as a category B drug in pregnancy, indicating that animal studies have not demonstrated a risk to the fetus. Nevertheless, the drug crosses the placenta and is excreted into breast milk. Current evidence suggests that exposure levels during lactation are low; however, caution is advised in the first trimester and when treating infections that could compromise maternal health.

Pediatric Considerations

In children, dosing is weight‑based, typically 10–15 mg kg^-1 on day 1 followed by 5–10 mg kg^-1 daily for 4 days. The drug is generally well tolerated; however, growth and developmental monitoring is recommended in prolonged courses.

Geriatric Considerations

Age‑related changes in renal and hepatic function may alter azithromycin disposition. Monitoring for cardiac arrhythmias is particularly relevant in this population due to increased prevalence of conduction abnormalities.

Renal and Hepatic Impairment

Renal impairment has a limited impact on azithromycin pharmacokinetics, but caution is warranted in severe chronic kidney disease (eGFR < 15 mL min^-1 1.73 m^-2). Hepatic impairment may prolong drug exposure; dose adjustments are not routinely required in mild to moderate disease but should be considered in severe hepatic dysfunction.

Summary/Key Points

• Azithromycin is a second‑generation macrolide with broad antibacterial activity and significant anti‑inflammatory properties.
• Its unique pharmacokinetics—high tissue distribution and prolonged half‑life—permit once‑daily dosing and short treatment courses.
• Approved indications include respiratory tract infections, sexually transmitted infections, and certain skin conditions; off‑label uses are common in chronic airway disease.
• Major adverse effects encompass gastrointestinal upset and QT interval prolongation; vigilant cardiac monitoring is advised in susceptible patients.
• Drug interactions primarily involve QT‑prolonging agents and hepatic transporter modulators; contraindications include macrolide hypersensitivity and severe hepatic impairment.
• Special populations—pregnant women, lactating mothers, children, the elderly, and patients with organ dysfunction—require dose adjustments or heightened monitoring based on individual risk profiles.

In practice, the choice of azithromycin should be guided by infection etiology, patient comorbidities, and local antimicrobial resistance patterns. The drug’s pharmacologic characteristics enable effective therapy while minimizing dosing burdens, yet careful assessment of cardiac risk and drug interactions remains paramount to ensure patient safety.

References

1. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
8. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.